stocks logo

STAA

-
$
0.000
0(0.000%)1D
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
26.820
Open
26.410
VWAP
25.99
Vol
1.95M
Mkt Cap
1.32B
Low
24.590
Amount
50.58M
EV/EBITDA(TTM)
--
Total Shares
49.13M
EV
1.13B
EV/OCF(TTM)
--
P/S(TTM)
5.72
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Show More
AI Stock Picker

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
91.26M
+105.9%
0.070
-154.82%
73.29M
+72.08%
0.030
-102.99%
77.97M
+59.28%
0.082
-115.97%
Estimates Revision
The market is revising Downward the revenue expectations for STAAR Surgical Company (STAA) for FY2025, with the revenue forecasts being adjusted by -3.07% over the past three months. During the same period, the stock price has changed by -2.60%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.55%
In Past 3 Month
Stock Price
Go Down
down Image
-2.60%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
7 Hold
0 Sell
Hold
Current: 26.550
sliders
Low
28.00
Averages
28.00
High
28.00
Stifel
Buy
to
Hold
downgrade
$20 -> $28
2025-08-07
Reason
Stifel downgraded Staar Surgical (STAA) to Hold from Buy with a price target of $28, up from $20, following the proposed acquisition by Alcon (ALC). The acquisition makes sense strategically and the valuation paid appears attractive for Alcon, the analyst tells investors in a research note.
Stifel
Thomas Stephan
Buy
to
Hold
downgrade
$20 -> $28
2025-08-06
Reason
Stifel analyst Thomas Stephan downgraded Staar Surgical to Hold from Buy with a price target of $28, up from $20.
Sidoti
James Sidoti
Buy -> Neutral
downgrade
$28
2025-08-05
Reason
Sidoti analyst James Sidoti downgraded Staar Surgical (STAA) to Neutral from Buy with a $28 price target after Alcon (ALC) announced a definitive agreement to acquire Staar for $28 per share in cash.
Mizuho
Neutral
maintain
$17 -> $18
2025-07-16
Reason
Mizuho raised the firm's price target on Staar Surgical to $18 from $17 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Canaccord
Hold
maintain
$17 -> $20
2025-05-08
Reason
Canaccord raised the firm's price target on Staar Surgical to $20 from $17 and keeps a Hold rating on the shares. The firm said they delivered an expectedly tough Q1 in terms of its results, but the tone of the earnings call was more upbeat than expected especially given that guidance was withdrawn, and as a result, the firm is taking its estimates up.
Stephens & Co.
Mason Carrico
Hold
Reiterates
$17
2025-03-18
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for STAAR Surgical Co (STAA.O) is 60.07, compared to its 5-year average forward P/E of 74.21. For a more detailed relative valuation and DCF analysis to assess STAAR Surgical Co 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
74.21
Current PE
60.07
Overvalued PE
135.35
Undervalued PE
13.08

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
48.93
Current EV/EBITDA
42.23
Overvalued EV/EBITDA
105.19
Undervalued EV/EBITDA
-7.34

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
10.62
Current PS
26.55
Overvalued PS
18.13
Undervalued PS
3.11
Financial AI Agent

Financials

Annual
Quarterly
FY2025Q3
YoY :
+6.93%
94.73M
Total Revenue
FY2025Q3
YoY :
+330.17%
24.44M
Operating Profit
FY2025Q3
YoY :
-10.98%
8.88M
Net Income after Tax
FY2025Q3
YoY :
-10.00%
0.18
EPS - Diluted
FY2025Q3
YoY :
-173.87%
1.78M
Free Cash Flow
FY2025Q3
YoY :
+6.34%
82.21
Gross Profit Margin - %
FY2025Q3
YoY :
-322.44%
-17.15
FCF Margin - %
FY2025Q3
YoY :
-16.77%
9.38
Net Margin - %
FY2025Q3
YoY :
-100.00%
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
17
30.1M
USD
Months
0-12
10
16.0M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.1M
Volume
Months
6-9
2
2.7M
Volume
Months
0-12
3
465.8K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Intellectia AI SwingMax

STAA News & Events

Events Timeline

2025-11-07 (ET)
2025-11-07
10:11:40
Staar Surgical Reveals Changes to Alcon Merger Deal
select
2025-11-05 (ET)
2025-11-05
16:15:56
Staar Surgical announces Q3 earnings per share of 18 cents, below consensus estimate of 25 cents.
select
2025-11-04 (ET)
2025-11-04
11:54:53
Broadwood Criticizes Alcon's Misleading Attacks on Staar Surgical
select
Sign Up For More Events

News

8.5
11-07NASDAQ.COM
PinnedSTAAR Launches 30-Day Period to Pursue Better Offers Than Alcon Agreement
8.5
11-07Newsfilter
STAAR Surgical Reveals Changes to Alcon Merger Deal
9.0
11-04Yahoo Finance
Alcon and Broadwood Clash Over the Future of STAAR Surgical
Sign Up For More News

People Also Watch

stocks logo
PENG
Penguin Solutions Inc
21.690
USD
+0.37%
stocks logo
OCFC
OceanFirst Financial Corp
17.860
USD
-1.60%
stocks logo
PSFE
Paysafe Ltd
10.180
USD
-0.97%
stocks logo
AMSC
American Superconductor Corp
38.860
USD
+6.32%
stocks logo
OBK
Origin Bancorp Inc
35.450
USD
+0.88%
stocks logo
NG
NovaGold Resources Inc
8.190
USD
+4.46%
stocks logo
KRO
Kronos Worldwide Inc
4.400
USD
-6.78%
stocks logo
FSUN
Firstsun Capital Bancorp
32.670
USD
-2.36%
stocks logo
RCKT
Rocket Pharmaceuticals Inc
3.170
USD
-1.86%
stocks logo
PDM
Piedmont Realty Trust Inc
8.260
USD
-0.12%

FAQ

arrow icon

What is STAAR Surgical Co (STAA) stock price today?

The current price of STAA is 26.55 USD — it has decreased -0.3 % in the last trading day.

arrow icon

What is STAAR Surgical Co (STAA)'s business?

arrow icon

What is the price predicton of STAA Stock?

arrow icon

What is STAAR Surgical Co (STAA)'s revenue for the last quarter?

arrow icon

What is STAAR Surgical Co (STAA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for STAAR Surgical Co (STAA)'s fundamentals?

arrow icon

How many employees does STAAR Surgical Co (STAA). have?

arrow icon

What is STAAR Surgical Co (STAA) market cap?